Last reviewed · How we verify
P.O moxypen 500 mgx3/d for 5 days
Moxypen (amoxicillin) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking.
Moxypen (amoxicillin) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and preventing peptidoglycan cross-linking. Used for Bacterial infections (respiratory tract, urinary tract, skin and soft tissue, otitis media, sinusitis), Helicobacter pylori eradication (as part of combination therapy).
At a glance
| Generic name | P.O moxypen 500 mgx3/d for 5 days |
|---|---|
| Sponsor | Western Galilee Hospital-Nahariya |
| Drug class | Beta-lactam antibiotic (aminopenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Amoxicillin is a beta-lactam antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting the cross-linking of peptidoglycan strands. This disrupts cell wall integrity, leading to bacterial cell lysis and death. It is bactericidal and effective against a broad spectrum of gram-positive and some gram-negative bacteria.
Approved indications
- Bacterial infections (respiratory tract infections, otitis media, sinusitis, urinary tract infections, skin and soft tissue infections)
- Helicobacter pylori eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Rash
- Allergic reaction / anaphylaxis
- Abdominal pain
Key clinical trials
- Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: